Transcatheter Mitral Valve Implantation (TMVI)

The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach that is currently undergoing first-in-man trials. Below is a link to the paper with the latest evidence on the device and a link to the news release.

Bapat et al. 2014 Eurointervention

Edwards News Release

X0000_Edwards_Fortis transcatheter Mitral valve copy_0

About The Author

Structural Heart Disease Australia

Structural Heart Disease Australia is an incorporated association focused on education in valvular and structural cardiac diseases. It was started by group of echocardiographers, anaesthetists, clinical and interventional cardiologists, and cardiothoracic surgeons to provide a useful learning resource for medical professionals.

SHDA is supported by


Recent Tweets